PeptideStack

P21

Explore the P21 peptide, a synthetic CNTF derivative studied for its potential to promote neurogenesis, enhance cognition, and protect against Alzheimer's.

Last updated:

Administration
subcutaneous
Origin
Synthetic (CNTF Derivative)

Overview

The P21 peptide is a synthetic derivative of ciliary neurotrophic factor (CNTF) designed to cross the blood-brain barrier and promote neurogenesis. By mimicking the neurogenic effects of CNTF without triggering neutralizing antibodies, P21 has emerged as a promising research compound for cognitive enhancement. Researchers are investigating its potential to protect against neurodegenerative diseases like Alzheimer's by boosting synaptic plasticity and memory formation.

Potential Benefits

  • Enhanced Neurogenesis: P21 has been shown to stimulate the growth of new neurons in the dentate gyrus, a critical region for memory and learning.
  • Cognitive Enhancement: Animal studies indicate that P21 benefits include improved spatial memory and faster learning acquisition in behavioral tasks.
  • Neuroprotection: By upregulating brain-derived neurotrophic factor (BDNF), the peptide helps protect existing neurons from oxidative stress and amyloid-beta toxicity.
  • Synaptic Plasticity: Research suggests P21 increases the density of dendritic spines, facilitating better communication between neural networks.
  • Alzheimer's Disease Mitigation: Preclinical models demonstrate that P21 can reverse cognitive deficits associated with Alzheimer's disease pathology Blanchard et al., 2010.

Side Effects

Common side effects:

  • Injection site redness or irritation
  • Mild headaches
  • Temporary fatigue
  • Dizziness
  • Nausea

Rare or serious side effects:

  • Immune system sensitization
  • Unintended neuro-proliferation
  • Altered mood or anxiety
  • Severe allergic reaction

P21 is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.

Mechanism of Action

At the molecular level, the P21 peptide functions by binding to the CNTF receptor complex, initiating a cascade of intracellular signaling pathways. Unlike native CNTF, P21 selectively activates the JAK/STAT and PI3K/AKT pathways without inducing the formation of neutralizing antibodies that typically limit CNTF's efficacy. Through competitive inhibition, P21 also binds to the leukemia inhibitory factor receptor (LIFR), preventing the binding of native LIF and modulating neuroinflammation. This dual action ultimately upregulates the expression of neurotrophins like BDNF and NT-3, fostering an environment highly conducive to neurogenesis and synaptic repair.

Origin & History

The discovery of P21 stemmed from efforts to harness the neurogenic properties of ciliary neurotrophic factor (CNTF) while bypassing its poor blood-brain barrier permeability and immunogenicity. Researchers synthesized this small peptide sequence, corresponding to amino acids 148-151 of human CNTF, to create a more stable and bioavailable neurogenic agent. In early development, preclinical trials demonstrated P21's remarkable ability to reverse cognitive decline in mouse models of Alzheimer's disease. Currently, the P21 peptide remains strictly an experimental compound with a research-only approval status, lacking FDA approval for human clinical use.

Frequently Asked Questions

Research & Resources

Clinical Trials

Related Peptides